Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04150614 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 12, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary endpoint revised Secondary endpoints revised (6) · Site contact updatedv10 Show 2 more changesShow less
    • Secondary endpoints revised (6)
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  2. Primary and study completion dates: May 2024 to Jul 2026v9
  3. Re-verified, no change to tracked fieldsv8
  4. Primary and study completion dates: May 2022 to May 2024v7
  5. Primary and study completion dates: Oct 2021 to May 2022 Start date: Oct 24, 2019 to May 14, 2020v6 Show 1 more changeShow less
    • Start date: Oct 24, 2019 to May 14, 2020
Show 4 earlier versionsHide 4 earlier versions
  1. Secondary endpoints: details revised at 1 of 6 entries Study description shortened, about 14 wordsv5 Show 1 more changeShow less
    • Study description shortened, about 14 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study description revised Eligibility criteria shortened, about 5 wordsv4 Show 1 more changeShow less
    • Eligibility criteria shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study title expanded, about 2 wordsv3 See this version in full on ClinicalTrials.gov ↗
  4. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications.
Trial Details
NCT Number NCT04150614
Lead Sponsor University of Illinois at Chicago
Conditions Nausea With Vomiting Chemotherapy-Induced
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov